BHP Shares Fall as Jansen Potash Project Costs Surge 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
WASHINGTON, DC, Jan. 6, 2016 (GLOBE NEWSWIRE) -- The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected David Simmons, Chairman and CEO of PPD, as its 2016 Chairman, and John Hubbard, President and CEO of Bioclinica, as Vice Chairman.
"ACRO plays a vital role in promoting the interests of the CRO industry globally," said Simmons. "Not only does ACRO represent the industry on legislative and regulatory matters but, increasingly, the association helps build relationships with the sponsor, research site, investigator and patient communities. I look forward to leading the organization in 2016 as we pursue a focused and productive agenda."
|
|||||
Simmons added that, in addition to its legislative and regulatory priorities, ACRO is exploring further ways to benefit the industry in areas such as patient recruitment, workforce development and clinical trial efficiency.
"ACRO successfully advanced CRO industry interests in 2015 by influencing health and tax policy in the United States and navigating the implementation of the Clinical Trial Regulation in the European Union," said ACRO Executive Director Doug Peddicord, Ph.D. "We will build on our successes this year and continue to promote our industry through our robust communications and advocacy programs."
ACRO also elected as officers: Judd Hartman, General Counsel of PPD, as Treasurer; and Maria Kraus, Executive Vice President of Corporate Development and Strategy at Bioclinica, as Secretary.
About ACRO
The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics, and medical devices. The Association provides an active voice for the CRO industry globally. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ more than 110,000 professionals worldwide and conduct research in 142 countries. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel. Facebook. RebelMouse.
A photo accompanying this release is available at:
http://www.globenewswire.com/newsroom/prs/?pkgid=38345
CONTACT: John Lewis
[email protected]
202-464-9340
